February 28th, 2019
In participation of Rare Disease Day, iMetabolic Biopharma Corporation (iMBP) is pleased to announce that they have partnered with the FCS Foundation to create a strategic awareness campaign focused on Familial Chylomicronemia Syndrome (FCS). FCS is a devastating rare disease that prevents sufferers from normally metabolizing dietary fats. Without an approved therapeutic option, iMBP stands hand in hand on the front line with sufferers of this disease to find a solution. However, it all begins with awareness.
Download the full announcement at
For more information on the FCS Foundation, please visit https://www.livingwithfcs.org/.
February 7th, 2019
The management team of iMetabolic Biopharma Corporation (Tempe, AZ) is pleased to welcome Mr. André Harrell as it its newest member to the team. With a career spanning over three decades in commercial leadership roles, Mr. Harrell currently is President and CEO at AH2 & Beyond Consulting; specializing in global commercial strategies and corporate development. André’s worked with fortune 100 companies with experiences that have spanned both domestic and international in key executive leadership roles that include: Global Brand Product Marketing, Business Development, Mergers & Acquisitions, Pricing Margin Management, and Global Commercial Operations.
Mr. Harrell will be joining Dr. Martin Emanuele (Visgenx) on the Business Advisory Board and will undoubtedly become a great contributor to the company.
November 28th, 2018
The management team of iMetabolic Biopharma Corporation (Tempe, AZ) is pleased to welcome Dr. Kirkwood A. Pritchard Jr. as it its newest member to the team. With a career spanning over 35 years, Dr. Pritchard is a Professor of Surgery with Tenure at the Medical College of Wisconsin (Milwaukee, WI). His current area of interest is in cardiovascular disease and stroke; which is strongly supported by his background in lipid metabolism and dyslipidemia. Dr. Pritchard received his Ph.D. from The Ohio State University and has since amassed a large number of notable achievements including over 125 peer reviewed publications and several million dollars in NIH grant awards.
Dr. Pritchard will be joining a notable team on the company’s Scientific Advisory Board. Other members include Drs. Gerald I. Shulman (Yale School of Medicine/HHMI), Randall W. Nelson (ASU/retired), Christopher Larson (Sanford Burnham Presbys Medical Discovery Institute), Martin Emanuele (LifeRaft, Inc) and Michael Briggs (Woodland Pharmaceuticals, LLC).
November 21, 2018
Ligand Pharmaceuticals (San Diego, CA; NASDAQ: LGND) announced that it has entered into a partnership agreement with iMetabolic Biopharma Corporation (iMBP), an early stage startup company based in Tempe, AZ developing novel precision medicine therapeutics for the treatment of obesity related diseases. Specific financial information of the agreement were not disclosed, but did include Ligand taking an equity position within the startup company.
In a statement from iMBP Founder & CEO Dr. Urban A. Kiernan, "We are fortunate to have identified a partner in Ligand Pharmaceuticals at such an early stage of our evolution. This is a very exciting time for our company, team and shareholders."
Follow the link below to Business Wire press release.
November 19, 2018
Dr. Urban A Kiernan, CEO of iMetabolic Biopharma Corporation (Tempe, AZ), appeared in the latest issue of CEO CFO Magazine.
The link to the interview is found below.
September 17th, 2018
iMetabolic Biopharma Corporation (iMBP) has announced it has taken steps in making its early stage drug a viable candidate for the treatment of the orphan disease Familial Chylomicronemia Syndrome (FCS). FCS is a rare genetic disorder that inhibits the body from being able to digest dietary fats. High levels of these fats can lead to several life-threatening complications. Last month the FDA denied approval of the drug Volanesorsen, a jointly sponsored program by Ionis/Akcea as a treatment for regulating blood fat for FCS patients. From disclosed portions of the FDA response, the reasoning was based on the overall safety profile of Volanesorsen. With the FCS community still searching for a therapeutic option, iMBP understands the gravity of this challenge.
In a statement from iMBP’s CEO Dr. Urban Kiernan, “Our team recognizes the burden felt by FCS patients and their families. It was heart breaking to see a drug (Volanesorsen) raise so much hope to become the first approved therapy to help patients with this debilitating disease and to only come up short. As iMBP is developing a drug that can also be used to truly help these patients in a safe and effective manner; we are obligated to take on the additional task to do our best to get these patients a treatment option that they deserve.”
For more information of FCS, please visit http://fcs.raredr.com/